Regenicin, Inc. (RGIN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Little Falls, NJ, United States. Der aktuelle CEO ist Randall E. McCoy.
RGIN hat IPO-Datum 2009-11-16, 3 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $15.35K.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
